Asymmetric dimethylarginine and neonatal-related diseases / 国际儿科学杂志

Asymmetric dimethylarginine(ADMA) is an endogenous inhibitor of nitric oxide synthases(NOS),which is a risk marker of cardiovascular endothelial dysfunction.Recent studies found that ADMA was a predictor not only for acute cardiovascular disease,but also for critical illness and mortality.Studies have found that exogenous ADMA altered lung function and induced apoptosis in animal experiments and vitro experiments.The levels of plasma ADMA significantly increased in children with hypoxia,PPHN,brain damage,and preterm infants who required mechanical ventilation.ADMA could be a independent risk factor to predict neonatal complications and death.